A major challenge for HIV-1 vaccine research is developing a successful immunization approach for inducing broadly neutralizing antibodies (bnAbs). A key shortcoming in meeting this challenge has been the lack of animal models capable of identifying impediments limiting bnAb induction and ranking vaccine strategies for their ability to promote bnAb development. Since 2010, immunoglobulin knockin (KI) technology, involving inserting functional rearranged human variable exons into the mouse IgH and IgL loci has been used to express bnAbs in mice. This approach has allowed immune tolerance mechanisms limiting bnAb production to be elucidated and strategies to overcome such limitations to be evaluated. From these studies, along with the wealth of knowledge afforded by analyses of recombinant Ig-based bnAb structures, it became apparent that key functional features of bnAbs often are problematic for their elicitation in mice by classic vaccine paradigms, necessitating more iterative testing of new vaccine concepts. In this regard, bnAb KI models expressing deduced precursor V(D)J rearrangements of mature bnAbs or unrearranged germline V, D, J segments (that can be assembled into variable region exons that encode bnAb precursors), have been engineered to evaluate novel immunogens/regimens for effectiveness in driving bnAb responses. One promising approach emerging from such studies is the ability of sequentially administered, modified immunogens (designed to bind progressively more mature bnAb precursors) to initiate affinity maturation. Here, we review insights gained from bnAb KI studies regarding the regulation and induction of bnAbs, and discuss new Ig KI methodologies to manipulate the production and/or expression of bnAbs in vivo, to further facilitate vaccine-guided bnAb induction studies.
HIV-1 strains, that is, broadly neutralizing antibodies (bnAbs). Studies demonstrating absolute protection afforded by passive transfer 4, 5 or transduction 6 of monoclonal bnAbs, prior to viral challenge, lend support to this notion.
Although bnAbs have yet to be elicited by vaccination, 7 recent
findings that bnAbs do develop over years in a subset of HIV-infected subjects [8] [9] [10] [11] [12] provided renewed impetus for the HIV-1 vaccine field to devise new immunogens and strategies to induce them. Highthroughput Ig cloning methodologies have enabled the discovery of many new monoclonal bnAbs over the past few years, providing two key insights for HIV vaccine design. First, the discovery of these new HIV-1 bnAbs has provided key structural information regarding five distinct, but conserved, regions in the Env trimer in which their epitopes cluster, thus providing a blueprint of the vulnerable regions a bnAb-eliciting vaccine can exploit. These five targets are the gp120 CD4-binding site (CD4bs), the gp41 membrane proximal external region (MPER), and three peptide/glycan epitope-rich regions, either found in gp120 V1/V2 or V3 variable loops (i.e. the trimer apex and high-mannose patch, respectively), or in the gp120/gp41 bridging interface. 13, 14 The second insight is that bnAbs have an intriguing set of shared characteristics, despite their independent origins. Thus, in addition to utilizing a restricted set of human V H genes, 3 an unusually low surface density of Env trimers on HIV virions, 16, 17 and extensive SHM may provide structural flexibility to counter natural variation in otherwise relatively conserved bnAb-targeting regions. 3, 13, [18] [19] [20] It has now become increasingly clear that these same unusual bnAb traits pose daunting immunologic obstacles to initiating and/or completing the maturation of bnAbs by vaccine strategies [reviewed in (21) (22) (23) ]. For example, long HCDR3s and in vitro polyreactivity are negatively correlated with function, specificity, and/or frequency of B cells in the pre-immune repertoire, due to difficulties in their Immunogloblulin (Ig) heavy chains (HCs) pairing to surrogate or bona fide Ig light chains (LCs) and/or invoking central B-cell tolerance controls. [24] [25] [26] [27] Furthermore, excessive SHM generated during bnAb development in the setting of infection, if also required during vaccination, would necessitate humoral responses involving highly disfavored, protracted affinity maturation (AM) pathways [28] [29] [30] [31] that are likely impractical and/or unsafe to induce. Despite the daunting set of challenges such unusual traits pose, the good news is that bnAbs exhibit varying degrees of these features and/or combinations of them. For instance, while CD4bs 'VRC01 class' bnAbs approach 50% SHM levels, 3 they lack initial self-reactivity and have typical sized HCDR3s. On the other hand, bnAbs targeting the high-mannose patch (despite having long HCDR3s 13 ) or those directed to the MPER (despite exhibiting considerable self-reactivity 32 ), tend to accumulate fewer SHMs, relative to CD4bs-specific bnAbs. 23, 33, 34 Given the identification of these formidable, yet not insurmount- from patients with prolonged HIV-1 infection, where bnAb-specific maturation issues, for example, extensive host/virus co-evolution 35, 36 or potential purifying selection forces 23, 30, 31, 37 could generate high SHM, but other confounding issues, irrelevant to bnAb formation, for example, inflammation 38 or B-cell dysregulation, 39 may produce general 'mutational noise'. Additionally, while one study has argued such extreme SHM levels (up to 48% VDJ aa mutation) confer FRW regions the necessary flexibility to deal with viral diversity, 18 in vitro mutagenesis studies have shown only 25%-30% of such high total SHM levels are functionally required. 40 However, this latter report does not take into account the nonlinear acquisition of SHM accumulated during AM. 29 Nevertheless, this issue is critical to resolve because if the minimal SHM needed for bnAb generation can be defined during vaccination and the level is considerably less than what occurs during infection, it would provide strong rationale to focus on devising vaccination strategies that 'short-circuit' rather than recapitulate the evolutionary pathways deciphered during infection. Likewise, for the traits of long HCDR3 and in vitro poly/autoreactivity, understanding their in vivo tolerizing effects across bnAb lineages against distinct Env regions is critical for defining their tractability as vaccine targets, because immunization strategies can either be directed to lineages with no self-reactivity, or alternatively, focus on modulating tolerance, such as seeking to provide regimens with stronger or more specific BCR, Toll-like receptor (TLR), or helper T-cell signals. [41] [42] [43] [44] [45] A second gap in knowledge toward developing a bnAb-eliciting vaccine is understanding whether vaccination can evolve bnAbs targeting more than one Env region, to a reasonable degree of breadth. Because viral escape mutants may develop in response to bnAbs targeting only a single region, 3, 35 and passively infused combinations of two, lesspotent/broad bnAbs to distinct targets can synergize in conferring near-complete breadth, 3, 34, 46, 47 Regardless of which types or combinations of immunogens are required in prime/boost strategies, this issue, as with the others mentioned above, would also benefit highly from more comprehensive testing in more practical in vivo platforms. 
| Central deletion and other B-cell tolerance mechanisms observed in bnAb KI models
Notably, although central deletion is profound in 2F5 and 4E10
VDJ+VJ KI models, it is not complete, as small populations of residual KI B cells are observed in the periphery of both, which could serve as targets for immunization. These residual KI B cells, however, were found to be limited by additional 2° tolerance mechanisms, including having poor BCR expression and signaling, characteristic of being anergic (functionally silenced), 89 and/or undergoing extensive LC receptor-editing events that mitigated self-reactivity and promoted rescue from clonal deletion [84] [85] [86] ( Figure 1 ). Despite having undergone extensive LC editing, many peripheral clones remained anergic, 84, 85 which along with the finding that a version of this KI model in which V H DJ H rearrangements expressed alone could invoke profound tolerance controls, [83] [84] [85] [86] [87] suggested that the 2F5/4E10 HC self-reactivities are dominant and cannot be fully vetoed by LC editing.
In terms of tolerance mechanisms controlling bnAb induction, the 2F5 VDJ+VJ strain, as the prototype bnAb KI tolerance model, has been most extensively evaluated to date ( Figure 1 ), and in addition to the processes of deletion, anergy, and receptor editing noted above, further studies have also led to the identification of a novel process termed Affinity Reversion/Ab redemption that represents a 'last resort' mechanism for anergic 2F5 + B cells that persist into mature B-cell subsets (including the aforementioned 'uneditable' anergic population)
for escaping apoptosis via purifying selection. 37 The same phenomenon has independently been uncovered and elegantly described in a well-controlled set of HEL KI models by Goodnow and colleagues.
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Recently, evidence for this process in limiting completion of bnAb maturation has been observed in the development of 2F5-like lineages in vaccinated primates. 90 Based on these emerging data in support of this process, one hypothesis to account for the high degree of SHM in bnAbs has been proposed, wherein the incomplete overlap of bnAb epitopes with self-antigens creates a selection 'tug-of-war' during AM: for HIV neutralization affinity, but against self. 23, 31, 91 Since bnAbs appear to require protracted AM pathways during HIV co-evolution in chronically infected subjects, 3 it will now be of interest to explore the relevance of Affinity Reversion during vaccine approaches aimed at eliciting other bnAb lineages, since such a mechanism, if general- rearrangements into B cells, fails to pass multiple tolerance checkpoints. [83] [84] [85] However, while nearly all 2F5 + B cells are clonally deleted at the 1st checkpoint (the pre->imm. B transition), 5% populate the periphery, but most have been functionally silenced. Among these residual anergic B cells, a minority removes all self-reactivity and escape tolerance altogether, but due to the inability of 2F5 receptor editing to remove dominant 2F5 HC self-reactivity, purifying selection occurs in later development, by a T-dependent, SHM-driven process, 'Affinity Reversion/ Ab Redemption'. to self-antigens do not reflect those capable of invoking tolerance at physiologically relevant sites of B-cell encounter. Secondly, because host tolerance occurs as a continuum of developmental checkpoints and processes 22, 91 only through analysis in Ig KI models can precise mechanisms responsible and most critically, ways to manipulate them, be identified, as has been previously done to examine various auto-Ab specificities.
Although potential in vivo tolerization has not yet been evaluated for most 2nd generation bnAbs or their precursors, several initial insights have begun to emerge from studies in newer KI models expressing reverted/unmutated versions of these bnAbs. One such example is a study addressing whether high SHM levels in bnAbs can accumulate at least in part due to elimination of self-reactivity, which would predict a more stringent degree of tolerization in precursors. 57 In this study, mice expressing 2F5's unmutated ancestor (UA) V H DJ H + VκJκ rearrangements were generated, and found to be under more profound deletion and anergy controls relative to the original (mutated) 2F5 dKI mice, 90 demonstrating this is the case, at least in certain instances. Another example is a recent report in which a gl-3BNC60 VDJ+VJ KI model, co-expressing V germline-reverted
were found to exhibit extensive LC editing and peripheral anergy, 93 thus providing an initial clue that at least some CD4bs-specific bnAbs may also be controlled by tolerance. Interestingly, several other recent studies in settings other than KI models also support findings of considerable tolerance prevalence across bnAb ilneages, thus complementing the above-mentioned initial studies in newer (non-MPER bnAb) KI models. In one, a protein array of 9500 host proteins was used to screen a large array of HIV Abs (including many 2nd generation bnAbs), and found >2/3 were poly-and/or autoreactive, 94 including two of the most potent and broad ones, the MPER + bnAb 10E8 and the CD4bs-specific bnAb VRC01, both for which self-reactivity was not originally detected in standard in vitro assays. [95] [96] [97] Furthermore, in support of host controls limiting many (or most) bnAbs, is a new study supporting the corollary that bnAbs should be more easily generated in autoimmune patients (due to defective tolerance), which has been supported by anecdotal observations of disproportionately lower frequencies of SLE + patients with HIV infection. [98] [99] [100] [101] [102] In this recent study, two HIV-infected cohorts differing in their abilities to produce bnAbs were compared, and relative to subjects that failed to generate bnAb responses, those producing bnAbs had higher frequencies of circulating auto-Abs and CD4 + T-follicular helper cells and lower levels of T-regulatory cells. mice to produce high (mg/ml) titers of serum bnAb IgGs (Figure 1 ). and when passively administered to humans, 4E10 was biologically active and prolonged partial thromboplastin time, whereas no clinically adverse effects were reported in passive infusions with 2F5.
| KI mice as models to identify strategies to break bnAb anergy and test pathogenicity
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Importantly 
| GERMLINE-REVERTED BNAB KI MODELS FOR TESTING NEW HIV VACCINE STRATEGIES
| Induction of VRC01-like Abs in mouse models
VRC01-class antibodies (Abs) target the CD4bs of gp120. were removed. 40, 114 Nevertheless, SHM is a largely random process, and it is not technically feasible to direct the mutation machinery to a specific position. In order to hit the desired spot, unwanted mutations may be unavoidable. Thus, to elicit a matured VRC01-like Ab, immunization may need to induce more mutations than the minimal set. Lastly, the strong reactivity of the matured VRC01 toward UBE3A may limit the induction of this type of Ab. 94 Since the VRC01 paratope for UBE3A and gp120 appear to overlap, VRC01 affinity for the two antigens may go hand in hand. During immunization, when VRC01
intermediates have gained sufficient affinity for UBE3A, further maturation may run into roadblocks of tolerance control.
Since conventional vaccination strategies have so far failed to elicit bnAbs, a sequential immunization scheme has been proposed to overcome the impasse. A Abs. Through a series of structure-based modifications, the eOD-base was eventually evolved into a broad gl-VRC01 binder, eOD-GT8. 
| Immunization studies in the VRC01gH
KI model
The efficacy of eOD-GT8 as a priming immunogen was evaluated in a VRC01 KI model (Figure 2A) . 118 In this model, a rearranged gl-VRC01 Given low SHM levels after the priming step, VRC01-like Abs at this stage may not be able to effectively recognize native Env proteins.
This consideration prompted the development of bridging immunogens for initial boosting. 119 One such immunogen, BG505coreGT3, contains the complete gp120 core of BG505 Env, including inner domain and bridging sheet, which were absent in the streamlined eOD-GT8. In addition, BG505coreGT3 contains fewer mutations than eOD-GT8 so that its CD4bs is more native-like. An important property of BG505coreGT3 is that it binds mature VRC01-class Abs with >1000-fold higher affinity than the germline reverted counterparts. Thus, boost immunization with BG505coreGT3 would promote the maturation of VRC01-like precursor Abs. As an alternative boosting immunogen, BG505GT3 was also produced as native Env trimers, that is, BG505 GT3 SOSIPs. To test the efficacies of these bridging immunogens, VRC01gH mice were immunized with two immunization protocols. 119 In one scheme, the mice were primed with eOD-GT8 60mer, then boosted once with BG505 GT3 nanoparticles, and finally boosted twice with BG505 SOSIP N276D. In the second scheme, the mice were primed with eOD-GT6 60mer, then boosted once with BG505 GT3 SOSIP, and finally boosted twice with BG505 SOSIP N276D. Both immunization protocols elicited CD4bs-specific
Abs that were composed of VRC01gH and mouse LCs with 5-aa CDR L3. Additionally, substantial levels of SHM were induced, and some of the mutations corresponded to those found in VRC01-class bnAbs.
Particularly remarkable was the strong enrichment for the conserved E residue within the 5-aa CDR L3; in fact, some CDR L3s have acquired the complete consensus QQYEF motif of VRC01-class bnAbs. Along with induction of SHM, these immunizations also elicited Abs that were able to neutralize multiple tier 2 HIV-1 isolates with the N276 mutation. Two of these could neutralize a tier 2 virus N276 mutant with comparable potency as the mature VRC01 Ab, and were able to weakly neutralize the native form of this viral isolate that has the intact N276 glycosylation site. Other viral isolates with intact N276 glycosylation site remained refractory to neutralization by these and other cloned Abs. Thus, these boosting regimens matured VRC01-like Abs to an intermediate stage, validating the strategy of sequential immunization as an effective approach to mature VRC01-like Abs.
| Immunization studies in the 3BNC60
KI model
Immunization studies have also been carried out in KI models for an- Ab with about 10-fold higher affinity than gl-3BNC60. 
| Immunization studies in KI models with diverse VRC01 precursor repertoires
Both VRC01gH and 3BNC60 KI models express rearranged IGHV1-2*02 HCs with fixed HCDR3 from mature Abs. In contrast, in the human Ab repertoire, IGHV1-2 is linked to diverse HCDR3s, a subset of which may be compatible with the development of VRC01-like Abs. Thus, a key issue is to assess immunogens in a setting where the human IGHV1-2 is expressed in association with diverse HCDR3s.
One way to achieve this is by generating a KI model where the human IGHV1-2 segment substitutes for one of the mouse V H segments. 
| Immunization studies in Kymab mice
Although the VH1-2 mouse model contains a diverse repertoire of IGHV1-2*02 HCs, the frequency of B cells expressing IGHV1-2*02 HC (45%) is much higher than that in human Ab repertoire (approximately 3%). [123] [124] [125] To evaluate the efficacies of eOD-GT8 as a priming immunogen in a fully polyclonal environment, immunization studies have also been done in Kymab mouse, in which the complete human IgH, Igκ, and Igλ variable region repertoire were incorporated into the corresponding mouse loci. 126 In Kymab mice, the human IGHV1-2 HC represents about 1% of the Ab repertoire, lower than, but close to, that of human Ab repertoire (approximately 3%). [123] [124] [125] However, the frequency of 5-aa CDRL3s in Kymab mouse is 0.018%, which is lower than that in humans (approximately 0.9%) by 50-fold. 123 Taking into account that mice have fewer B cells than humans, VRC01-like precursors are expected to be more rare in Kymab mice than in humans.
Consistent with this prediction, no VRC01-class B cells were identified by eOD-GT8 sorting among 300 million B cells from naive Kymab Third, the accommodation of N276 glycosylation appears to be a bottleneck for VRC01-like Ab development. In mature VRC01 Abs, CDRL1 truncation or mutation helps to accommodate the N276 glycan. Some of the elicited Abs from the immunized VRC01 mouse models utilized mouse LCs with short CDRL1s, [118] [119] [120] 122 and these Abs may eventually overcome the N276 glycan obstruction with additional AM. Fourth, neutralization activities were induced in three types of VRC01 models (VRC01gH, 3BNC60, and VH1-2). However, in these mouse models, VRC01 HCs and/or LCs were expressed at much higher frequencies than those in humans. On the other end of the spectrum, Kymab mice offer a potentially even harder condition than that in humans to elicit VRC01-class Abs. Although the eOD-GT8 priming has successfully elicited VRC01-class precursor Abs in a fraction of immunized Kymab mice, it would be challenging to mature these precursor Abs into nAbs. In a complex Ab repertoire, boost immunization with more native forms of Env antigens, as those employed in the other three VRC01 mouse models, would likely induce irrelevant Ab responses, which may dominate over the development of VRC01-class Abs.
| Induction of PGT121-like Abs in KI models
The PGT121 lineage of bnAbs target the V3 and V1 regions near the apex of the Env trimer. 127, 128 The epitopes of this class of bnAbs are complex, involving a combination of glycans and peptides.
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Induction of PGT121-class Abs faces some of the same obstacle as those for other bnAbs, namely, low precursor frequency and high SHM.
PGT121-class bnAbs employ a long 26-residue HCDR3 to penetrate through the glycan layer to interact with the underlying peptides;
HCDR3s of such length are rare in the human Ab repertoire. SHM frequencies for PGT121-class bnAbs, although lower than those in VRC01-class Abs, are still far above average, and their LCs also contain indels. Tolerance control may not be a major concern for PGT121-class Abs, as PGT121 exhibits no overt poly-/autorectivity at least in vitro. 94 The sequential immunization strategy is equally applicable to the induction of PGT121 class of Abs. Similar to other reverted bnAbs, gl-PGT121 Abs exhibited no appreciable binding affinity toward WT Env proteins. 131 Through multiple rounds of mutagenesis and selection, BG505 Env proteins was engineered into gl-PGT121 binder (10MUT and 11MUTB). 
| CONCLUSIONS AND FUTURE PERSPECTIVES
Tremendous progress has been made in this current 'golden era' of bnAb discovery, where information emerging from cloning and This largely depends both on the molecular characteristics a bnAb has acquired, as well as the information that is (or will be) available regarding its evolutionary pathway. For example, for a bnAb in which information regarding its molecular evolution is not available (or limited), the best-suited, existing KI model is one having unrearranged V H and/or J H segments knocked in (Figure 4 Model 'B'), made like the VH1-2 KI model. 122 This platform, due to its ability to preferentially rearrange V H 1-2, can express a repertoire enriched for
Types of Ig-humanized mouse models to study vaccine-guided bnAb development. Pictorial representations of the structural organization of targeted alleles from various kinds of current or planned Ig-humanized models are shown, relative to the WT murine allele. For simplicity, only HC loci are depicted, and only at one allele. Models that have been published (with corresponding references to the right), or models which are being generated, are denoted in black text (Models A, B, and E), while theoretical germline/unrearranged models (that could be made to further bridge the current gap between physiological relevance and practicality to study 'difficult to infer, long HCDR3' bnAb specificities; Models C and D), are annotated in blue text. Mouse and human germline-derived sequences/segments are depicted in red and blue, respectively. Denoted as a green segment in the A1 type of models are 'mutated' HCDR3s from the human bnAbs VRC01 and PGT121, that is, from either the original/mature VRC01 bnAb, but with a single mutation to remove an unpaired cysteine, 118 or for PGT121, from the least mutated lineage member. 132 The intergenic control region 1 (IGCR1) normally found in WT HC loci is denoted by a large circle, which has been removed in models B, C, D, to further facilitate rearrangement of D-proximal (V H 81X-positioned) V H segment(s) of interest. p=promoter region; L=leader sequence Model 'E'), which rarely express such bnAb rearrangements, thus making iterative study of bnAb development impractical. On the other hand, if complete virus and Ab co-evolutionary pathways from which a bnAb develops have been elucidated via comprehensive longitudinal sampling, including having a high-probability inference of this bnAb's unmutated common ancestor (UCA), the goal may be somewhat different. For example, there would be strong rationale to employ the 'B-cell lineage immunogen design' vaccine strategy, 61 in which priming is done with the lineage's original transmitted founder virus, and sequential boosting is done using Env immunogens generated from the viral isolates that co-evolved with its progressively matured Ab intermediates. In such instances, where the study focus is to use a it will now be feasible to accelerate the production bnAb KI models so that a large array can be made, thus making it more feasible to analyze bnAb development across multiple lineages, including those targeting Env regions other than the CD4bs. Furthermore, with the F I G U R E 5 High-throughput in vivo expression of bnAbs in chimeric mice using RDBC. Shown are the two major steps involved in generating bnAb KI chimeric mice using RAG-dependent blastocyst complementation: generation of blastocyst chimeras by microinjection of bnAb KI ES cells (A), and implantation of blastocysts in pseudopregnant RAG2 −/− foster mothers, resulting in chimeric offspring (B) whose lymphocytes all express the knocked in bnAb specificity and can be used for immunization. Shown as an optional step is germline transmission of bnAb KI allele to generate a standard KI model (C), which can be pursued if more in-depth studies with a particular model are desired 25 One specific example of such an approach would be employing a Cre-loxP inversional recombination system to conditionally express a 'passenger' bnAb specificity in the periphery, analogous to strategies previously used to modify B-cell specificities in memory B cells. 144 Another example of further refinements to bnAb KI models revolves around mechanistic issues of SHM in bnAb maturation, including specifically, whether high SHM levels are inherent to and/or generally required (or perhaps even detrimental) for bnAb development, and if so, whether inducing such high levels or unusual, insertion/deletion events associated with such high SHM rates, but key for function of many bnAbs, 145 is both feasible and safe for eliciting via vaccines. In this regard, examples of KI models that could be generated to facilitate such questions are those co-expressing passenger KI alleles, in order to better dissect the instrinsic mutability component of bnAb responses, 146 as well as those bred to other genetically modified KI/KO lines with altered SHM and/or GC B-cell selection. One example of such a 'compound' bnAb KI line is one generated via crossing to a dominantly active form of polymerase-ζ, that is, rev3 KI mice, 147 in which SHM rates are accelerated, and thus SHM levels during immunization-guided bnAb lineage development would be forced to reach those seen during chronic infection.
